病理性近视脉络膜新生血管的诊断与治疗

doi:10.6040/j.issn.1673-3770.0.2019.545

摘要/Abstract

摘要： 病理性近视是全世界范围内引起患者视力下降的主要原因之一,在亚洲国家尤为多见。而脉络膜新生血管是病理性近视的最严重并发症之一,它可以引起眼底黄斑区病变,导致视力下降,出现中心暗点,视物变形,视野缺损等,如长期不治疗可能导致失明。光学相干断层扫描、光学相干断层扫描血管成像、荧光素眼底血管造影等检查方法在诊断病理性近视继发的脉络膜新生血管中起到很大帮助,可以较为明确的显示新生血管的位置,大小等,不论其是否处于活动期。目前对于病理性近视引起的脉络膜新生血管主要治疗方法有光动力治疗及抗血管内皮生长因子(VEGF)治疗,近年来,玻璃体腔内注射抗VEGF药物成为病理性近视与脉络膜新生血管的首选治疗方法,通过减少新生血管的形成,减轻黄斑区水肿,从而达到改善视力及更好的预后效果。论文主要综合整理近期关于病理性近视脉络膜新生血管的诊断及治疗的研究,为临床工作提供帮助。

关键词: 病理性近视, 脉络膜新生血管, 诊断与治疗

Abstract: Pathologic myopia(PM)is a major cause of vision loss worldwide, particularly in Asian countries. Choroidal neovascularization(CNV)is a severe complication of PM, which can cause macular disorders, leading to central scotoma, metamorphopsia, visual field loss, and finally blindness if not treated. The advents of optical coherence topography(OCT), OCT angiography, and fundus fluorescein angiography are helpful in diagnosing CNV due to PM, which can show the position and size of CNV, whether active or passive. For the treatment, photodynamic and anti-vascular endothelial growth factor(anti-VEGF)therapies are widely applied. In recent years, administering the intravitreal anti-VEGF injection has become the first-line treatment for CNV secondary to PM. Many clinical studies have indicated that intravitreal anti-VEGF injections affect antagonizing neovascularization and reduce macular edema, thereby contributing to visual improvements and better long-term outcomes. This article provides an overview of the current diagnosis and treatment options for myopic CNV.

Key words: Pathologic myopia, Choroidal neovascularization, Diagnosis and treatment

中图分类号:

R774

任雨馨,赵博军. 病理性近视脉络膜新生血管的诊断与治疗[J]. 山东大学耳鼻喉眼学报, 2020, 34(5): 157-162.

参考文献

[1] Ruiz-Medrano J, Montero JA, Flores-Moreno I, et al. Myopic maculopathy: Current status and proposal for a new classification and grading system(ATN)[J]. Prog Retin Eye Res, 2019, 69: 80-115. doi:10.1016/j.preteyeres.2018.10.005.
[2] Ohno-Matsui K. What is the fundamental nature of pathologic myopia?[J]. Retina, 2017, 37(6): 1043-1048. doi:10.1097/iae.0000000000001348.
[3] Kyoko OM, Yasushi I, Timothy YYL, et al. Diagnosis and treatment guideline for myopic choroidal neovascularizationdue to pathologic myopia[J]. Prog Retin Eye Res, 2018, 63:92-106. doi: 10.1016/j.preteyeres.2017.10.005.
[4] Lai TY, Cheung CM. Myopic choroidal neovascularization: diagnosis and treatment[J]. Retina, 2016,36(9):1614-21. doi: 10.1097/IAE.0000000000001227.
[5] Ohno-Matsui K, Kawasaki R, Jonas JB, et al. International photographic classification and grading system for myopic maculopathy[J]. Am J Ophthalmol, 2015, 159(5): 877-883.e7. doi:10.1016/j.ajo.2015.01.022.
[6] Danny SC Ng, Timothy YY Lai, Cheung CMG,et al. Anti-Vascular Endothelial Growth Factor Therapy for Myopic Choroidal Neovascularization[J]. Asia Pac J Ophthalmol(Phila),2017,6(6):554-560. doi: 10.22608/APO.2017308.
[7] 丁雯芝, 邹俊. 病理性近视脉络膜新生血管发病机制的研究进展[J]. 眼科新进展, 2014, 34(10): 987-989. doi:10.13389/j.cnki.rao.2014.0274. DING Wenzhi, ZOU Jun. Research advances in pathogenesis of choroidal neovascularization of pathologic myopia[J]. Recent Advances in Ophthalmology, 2014, 34(10): 987-989. doi:10.13389/j.cnki.rao.2014.0274.
[8] Ikuno Y, Jo Y, Hamasaki T, et al. Ocular risk factors for choroidal neovascularization in pathologic myopia[J]. Invest Ophthalmol Vis Sci, 2010, 51(7): 3721-3725. doi:10.1167/iovs.09-3493.
[9] Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia[J]. Br J Ophthalmol, 2003, 87(5): 570-573. doi:10.1136/bjo.87.5.570.
[10] 孙明甡, 张丰菊. 病理性近视发病机制相关研究新进展[J]. 中国实用眼科杂志, 2014(4): 393-397. doi:10.3760/cma.j.issn.1006-4443.2014.04.001.
[11] Nakai K, Rogers MS, Baba T, et al. Genetic loci that control the size of laser-induced choroidal neovascularization[J]. FASEB J, 2009, 23(7): 2235-2243. doi:10.1096/fj.08-124321.
[12] Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up[J]. Ophthalmology, 2003, 110(7): 1297-1305. doi:10.1016/S0161-6420(03)00461-5.
[13] 占宗议, 李梓敬, 丁小燕. 病理性近视继发脉络膜新生血管诊疗现状与进展[J]. 中华眼底病杂志, 2016(1): 104-107. doi:10.3760/cma.j.issn.1005-1015.2016.01.029. ZHAN Zongyi, LI Zijing, DING Xiaoyan. Choroidal neovascularization secondary to pathologic myopia: a recent update on diagnosis and treatment[J]. Chinese Journal of Ocular Fundus Diseases, 2016(1): 104-107. doi:10.3760/cma.j.issn.1005-1015.2016.01.029.
[14] Laviers H, Li JO, Grabowska A, et al. The management of macular hole retinal detachment and macular retinoschisis in pathological myopia; a UK collaborative study[J]. Eye(Lond), 2018, 32(11): 1743-1751. doi:10.1038/s41433-018-0166-4.
[15] Querques L, Giuffrè C, Corvi F, et al. Optical coherence tomography angiography of myopic choroidal neovascularisation[J]. Br J Ophthalmol, 2017, 101(5): 609-615. doi:10.1136/bjophthalmol-2016-309162.
[16] Soomro T, Talks J, Medscape. The use of optical coherence tomography angiography for detecting choroidal neovascularization, compared to standard multimodal imaging[J]. Eye(Lond), 2018, 32(4): 661-672. doi:10.1038/eye.2018.2.
[17] Bruyère E, Miere A, Cohen SY, et al. Neovascularization secondary to high myopia imaged by optical coherence tomography angiography[J]. Retina(Philadelphia, Pa), 2017, 37(11): 2095-2101. doi:10.1097/IAE.0000000000001456.
[18] 张士胜, 廖华萍, 王康孙. 病理性近视脉络膜新生血管的激光治疗[J]. 医学综述, 2008, 14(19): 2959-2963. doi:10.3969/j.issn.1006-2084.2008.19.027. ZHANG Shisheng, LIAO Huaping, WANG Kangsun. Laser therapy of choroidal neovascularization secondary to pathologic myopia[J]. Medical Recapitulate, 2008, 14(19): 2959-2963. doi:10.3969/j.issn.1006-2084.2008.19.027.
[19] Newsom RS, McAlister JC, Saeed M, et al. Transpupillary thermotherapy(TTT)for the treatment of choroidal neovascularisation[J]. Br J Ophthalmol, 2001, 85(2): 173-178. doi:10.1136/bjo.85.2.173.
[20] Brancato R, Pece A, Avanza P, et al. Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia[J]. Retina(Philadelphia, Pa), 1990, 10(4): 239-243. doi:10.1097/00006982-199010000-00002.
[21] Ruiz-Moreno JM, de la Vega C. Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients[J]. Br J Ophthalmol, 2001, 85(9): 1041-1043. doi:10.1136/bjo.85.9.1041.
[22] Uemura A. Subretinal surgery for choroidal neovascularization[J]. Nippon Ganka Gakkai Zasshi, 2000, 104(9): 611-620.
[23] Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial: VIP report no. 3[J]. Ophthalmology, 2003, 110(4): 667-673. doi:10.1016/s0161-6420(02)01998-x.
[24] Lam DS, Chan WM, Liu DT, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up[J]. Br J Ophthalmol, 2004, 88(10): 1315-1319. doi:10.1136/bjo.2004.041624.
[25] Varano M, Iacono P, Giorno P, et al. Photodynamic therapy in subfoveal and juxtafoveal myopic choroidal neovascularization: a 10-year retrospective analysis[J]. Ophthalmologica, 2014, 231(4): 204-210. doi:10.1159/000357504.
[26] Willis J, Morse L, Vitale S, et al. Treatment patterns for myopic choroidal neovascularization in the United States: analysis of the IRIS registry[J]. Ophthalmology, 2017, 124(7): 935-943. doi:10.1016/j.ophtha.2017.02.018.
[27] Pece A, Milani P. Intravitreal aflibercept for myopic choroidal neovascularization[J]. Graefes Arch Clin Exp Ophthalmol, 2016, 254(12): 2327-2332. doi:10.1007/s00417-016-3396-9.
[28] Yan M, Huang Z, Lian HY, et al. Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia[J]. Acta Ophthalmol, 2019, 97(5): e813-e814. doi:10.1111/aos.13632.
[29] Moon BG, Cho AR, Lee J, et al. Improved visual outcome and low recurrence with early treatment with intravitreal anti-vascular endothelial growth factor in myopic choroidal neovascularization[J]. Ophthalmologica, 2017, 237(3): 128-138. doi:10.1159/000458160.
[30] Gonzalez CC, Juan RF, Jose V, et al. Long-term outcomes of two different initial dosing regimens of intravitreal ranibizumab used to treat myopic choroidal Neovascularization[J]. Ophthalmologica, 2017,238(4):196-204. doi: 10.1159/000478030.
[31] Kang EC, Seo JG, Kim BR, et al. Clinical outcomes of intravitreal bevacizumab versus photodynamic therapy with or without bevacizumab for myopic choroidal neovascularization: a 7-year follow-up study[J]. Retina(Philadelphia, Pa), 2017, 37(9): 1775-1783. doi:10.1097/IAE.0000000000001421.
[32] 阎静, 徐冲, 严立, 等. 雷珠单抗和PDT治疗病理性近视合并黄斑CNV的疗效比较[J]. 国际眼科杂志, 2018, 18(3): 498-501. doi:10.3980/j.issn.1672-5123.2018.3.22. YAN Jing, XU Chong, YAN Li, et al. Evaluation of Ranibizumab and PDT for patients with pathologic myopia and macular CNV[J]. International Eye Science, 2018, 18(3): 498-501. doi:10.3980/j.issn.1672-5123.2018.3.22.
[33] Rishi P, Rishi E, Bhende M, et al. Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre[J]. Br J Ophthalmol, 2016, 100(10): 1337-1340. doi:10.1136/bjophthalmol-2015-307802.
[34] Rinaldi M, Semeraro F, Chiosi F, et al. Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia[J]. Graefes Arch Clin Exp Ophthalmol, 2017, 255(3): 529-539. doi:10.1007/s00417-016-3498-4.
[35] Kang EC, Seo JG, Kim BR, et al. Clinical outcomes of intravitreal bevacizumab versus photodynamic therapy with or without bevacizumab for myopic choroidal neovascularization: a 7-year follow-up study[J]. Retina(Philadelphia, Pa), 2017, 37(9): 1775-1783. doi:10.1097/IAE.0000000000001421.
[36] Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia[J]. Ophthalmology, 2014, 121(3): 682-692.e2. doi:10.1016/j.ophtha.2013.10.023.
[37] Chen YX, Sharma T, Li XR, et al. Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: brilliance, a 12-month, randomized, double-masked study[J]. Retina(Philadelphia, Pa), 2019, 39(10): 1985-1994. doi:10.1097/IAE.0000000000002292.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed